
Owen Rask and Drew Meredith discuss the ACCC raid on WiseTech Global, Moderna's cancer vaccine breakthrough, and the latest ASX reporting season results.
Owen Rask and Drew Meredith break down the WiseTech Global (ASX: WTC) ACCC raid, Moderna’s (NASDAQ: MRNA) extraordinary cancer vaccine breakthrough, and the latest ASX reporting season results from Pro Medicus (ASX:PME), CSL Ltd (ASX:CSL), Challenger (ASX:CGF) and XRF Scientific (ASX:XRF). WiseTech Global (ASX: WTC) shares plunged after the Australian Competition and Consumer Commission (ACCC) executed a search warrant at the logistics software giant as part of an investigation into alleged competition law breaches. Meanwhile, in the US, Moderna (NASDAQ: MRNA) shares exploded higher after Moderna and Merck announced positive Phase 3 results for their personalised mRNA cancer vaccine in patients with high-risk melanoma — one of the biggest single-day moves we’ve seen in a major biotechnology stock. And it’s reporting season in Australia. Owen Rask and Drew Meredith dig into the latest FY26 financial results from some of the ASX companies investors are watching most closely, including Pro Medicus Limited (ASX: PME), CSL Limited (ASX: CSL), Challenger Limited (ASX: CGF) and XRF Scientific Limited (ASX: XRF). Topics covered – WiseTech Global (ASX: WTC): the ACCC search warrant…
Hosts: Owen Rask, Drew Meredith
Organizations: WiseTech Global, Australian Competition and Consumer Commission, Moderna, Merck, Pro Medicus, CSL Ltd, Challenger, XRF Scientific
Places: Australia, US
Explore listener stats, chart rankings, contacts and more on the Australian Investors Podcast podcast page.